SpringWorks Therapeutics, Inc.
12
6
7
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
8.3%
1 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
8%
1 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Role: lead
A Study of Mirdametinib in People With Central Nervous System Tumors
Role: collaborator
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Role: collaborator
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Role: collaborator
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Role: collaborator
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Role: collaborator
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Role: collaborator
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Role: collaborator
Nirogacestat in Ovarian Granulosa Cell Tumors
Role: lead
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Role: collaborator
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Role: lead
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
Role: collaborator
All 12 trials loaded